Stocks · News reference
Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — CalciMedica, Inc. (CALC)
Filed: 2026-10-16 AccNo: 0001193125-26-424203 Size: 137 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
CalciMedica Files Prospectus Supplement For Up To $25M At-The-Market Common Stock Offering
CalciMedica Regains Nasdaq Compliance
-SEC Filing